Related by context. All words. (Click for frequent words.) 79 mg QD 78 mg/m2/day 78 mg/m2 77 #mg/m# [001] 76 mg m 75 ug kg 75 #mg/m# [002] 75 administered subcutaneously 75 mg m² 75 lopinavir r 75 mg BID 74 4mg/kg 74 mg orally 74 mg kg dose 74 mg kg 73 mg dose 73 mg qd 73 8mg/kg 73 mg d 72 lispro 72 mg/m2 dose 72 mg TID 72 Peg IFN 72 mcg dose 72 CIMZIA TM 71 μg dose 71 mg/m2 IV 71 FOLFOX 71 plus ribavirin 71 nab paclitaxel 71 chlorambucil 71 #mg QD [002] 71 #mg/kg [002] 71 q#h 71 μg kg 70 μg 70 #mg/day [002] 70 microgram kg 70 ritonavir boosted 70 PREZISTA r 70 IV bolus 70 ribavirin RBV 70 LEXIVA r 69 atazanavir ritonavir 69 alfa 2a 69 mcg 69 mcg mL 69 mg ustekinumab 69 peg IFN 69 mg kg hr 69 pegylated interferon alfa 2a 69 FOLFIRI 69 saline placebo 69 #mg BID [003] 69 Q2W 69 peginterferon alfa 2b 69 mg/m2 administered 69 3mg/kg 69 lopinavir r arm 69 mcg BID 69 #mg BID [001] 69 QD dosing 69 mCi kg 69 FOLFOX4 69 certolizumab 69 dosing cohorts 69 mcg doses 69 active comparator 68 REBETOL 68 telaprevir dosed 68 peginterferon alfa 2a 68 insulin detemir 68 #.#mg/dL 68 mg administered orally 68 ritonavir boosted atazanavir 68 mcg albinterferon alfa 2b 68 achieved ACR# 68 budesonide pMDI 68 LEXIVA 68 mg subcutaneously 68 mcg QD 68 LPV r 68 FOLPI 68 Pegasys ® 68 rapid virologic response 68 #.#g/day 68 interferon alfa 2a 68 dacarbazine 68 subcutaneous injections 68 fluorouracil 68 #μg [002] 68 plus dexamethasone 68 plus prednisone 68 APTIVUS r 67 docetaxel chemotherapy 67 DOXIL 67 mg q8h 67 abacavir lamivudine 67 mg/# hr 67 mg/# hours 67 REYATAZ r 67 plus methotrexate 67 darunavir ritonavir 67 LANTUS R 67 PREZISTA ritonavir 67 mitoxantrone 67 oral rivaroxaban 67 ascending dose 67 evaluable patients 67 continuous intravenous infusion 67 mg RDEA# 67 oxycodone CR 67 irbesartan 67 #mg q8h 67 PegIFN 67 daily Infergen 67 5-FU/LV 67 PEG IFN 67 adalimumab 67 dose cohorts 67 carboplatin paclitaxel 67 subcutaneous dose 67 placebo p = 67 dose cohort 67 oral prednisone 67 mg doses 67 mg 66 mg eq 66 subcutaneous doses 66 FOLFOX4 alone 66 mg tid 66 achieved PASI 66 monotherapy 66 fluticasone salmeterol 66 COPEGUS 66 subcutaneous enoxaparin 66 epoetin alfa 66 VELCADE melphalan 66 q8h 66 clodronate 66 mg dosed 66 subcutaneously administered 66 mg dosed twice 66 inhalations twice 66 biochemical relapse 66 Pegasys plus Copegus 66 piperacillin tazobactam 66 q#d 66 microg 66 interferon alfa 2b 66 plus prednisone prednisolone 66 HBeAg seroconversion 65 comparator arm 65 intravenous dosing 65 interferon alfa 65 desvenlafaxine succinate 65 undetectable HCV RNA 65 mg kg IV 65 median PFS 65 rFSH 65 peg interferon 65 #mg/day [001] 65 HCV RESPOND 2 65 doxorubicin cyclophosphamide 65 log# copies mL 65 randomized #:# 65 oral allopurinol 65 tapentadol ER 65 pegylated interferon alfa 2b 65 intravenous bolus 65 mcg kg min 65 DLTs 65 octreotide LAR 65 log# IU mL 65 OADs 65 plasma HCV RNA 65 ng dL 65 GnRH agonist 65 μg doses 65 temsirolimus 65 etanercept 65 docetaxel 65 weekly subcutaneous injections 65 mg simvastatin 65 achieved statistical significance 65 q# 65 severe neutropenia 65 ACTEMRA TM 65 #ug [001] 65 intramuscularly 65 subcutaneous SC 65 Folfox 65 mg Lucentis 65 #mg dose [003] 65 low dose cytarabine 65 PegIFN RBV 65 tipranavir r 65 FOLFOX6 65 IFN α 65 timepoint 65 μg mL 65 log# 65 #mg QD [001] 65 CR CRu 65 8mg 64 intravitreal injection 64 estramustine 64 fluorouracil leucovorin 64 adjunctive placebo 64 plasma uric acid 64 #mg doses [002] 64 evaluable 64 IU mL 64 tenofovir emtricitabine 64 PegIntron 64 PEGINTRON TM 64 azacitidine 64 pegylated interferon alpha 64 VIRAMUNE 64 IFN alfa 64 PEGASYS ® 64 idarubicin 64 mg subcutaneous injection 64 unfractionated heparin 64 CIMZIA ™ 64 daunorubicin 64 Cmax 64 intermittent dosing 64 zonisamide SR 64 peginterferon alfa 2a #KD 64 dosing cohort 64 dosing intervals 64 azilsartan medoxomil 64 n = 64 Fludara 64 mCi m 2 64 #mg #mg #mg [003] 64 partial remissions 64 palonosetron 64 azathioprine 64 IU ml 64 CHOP chemotherapy 64 R# #mg BID 64 administered orally 64 carboplatin 64 peginterferon alfa 2a Pegasys 64 #μg [001] 64 progression TTP 64 biphasic insulin aspart 64 placebo dexamethasone 64 pegylated liposomal doxorubicin 64 #.#mg/kg [002] 64 IIIa inhibitor 64 PROMACTA 64 FOLPI regimen 64 mg subcutaneous 64 certolizumab pegol 64 PEG Intron 64 lumbar spine BMD 64 NPH insulin 64 patients evaluable 64 TDF FTC 64 ULORIC 64 nicardipine 64 potent CYP#A# inhibitors 64 ascending doses 64 fluticasone furoate 64 placebo intravenously 64 placebo 64 febuxostat 64 bendamustine 64 subcutaneously 64 alpha 2a 63 bolus injection 63 serum phosphorus 63 ug dose 63 Median PFS 63 evaluable subjects 63 aminotransferase elevations greater 63 BENICAR 63 tacrolimus ointment 63 serum urate 63 infliximab 63 pegylated interferon alpha 2a 63 injected subcutaneously 63 μmol L 63 dosed orally 63 amprenavir 63 gemcitabine 63 titrated 63 5mg/kg 63 PEGINTRON 63 peginterferon alfa 63 melphalan prednisone 63 Engerix B 63 PEG Interferon lambda 63 adriamycin 63 REYATAZ r arm 63 urate lowering therapy 63 mcg Albuferon 63 hypomagnesemia 63 relapsed MM 63 dosage regimens 63 Aptivus ® 63 intravenous REOLYSIN 63 EUFLEXXA R 63 fosamprenavir 63 dose escalation 63 dose regimens 63 efavirenz EFV 63 Doxil ® 63 Peginterferon 63 virologic failure 63 adefovir 63 BENICAR HCT 63 ribavirin therapy 63 vicriviroc 63 postdose 63 timolol 63 CCyR 63 posaconazole 63 kBq kg 63 creatinine clearance 63 mg iv peramivir 63 NATRECOR R 63 mL kg 63 flutamide 63 NovoLog ® Mix 63 HBeAg positive patients 63 inhaled corticosteroid ICS 63 Median progression 63 dose dexamethasone 63 peginterferon 63 edoxaban 63 salmeterol fluticasone 63 Acetate Rectal Suppositories 63 Tarceva TM 63 Locteron administered 63 Taxotere R 63 copies mL 63 mCi 63 tamsulosin 63 ACR# response 63 primary hypercholesterolemia 63 gout flares 63 dexamethasone Decadron 63 amoxicillin clavulanate 63 ng dl 63 mg q#h 63 #mg BID [002] 63 pg mL 63 pemetrexed 63 infliximab monotherapy 63 SCH # 63 TMC# r 63 sunitinib 63 vandetanib 63 diuretic chlorthalidone 63 budesonide formoterol 63 rizatriptan 63 esomeprazole 63 otamixaban 63 timepoints 63 hypokalemia 63 ATACAND 63 sorafenib Nexavar 63 tirofiban 63 elotuzumab 63 pegylated interferon 62 anakinra 62 Durezol 62 oral levofloxacin 62 mitomycin 62 QTcF 62 lopinavir ritonavir 62 abciximab 62 DAPT 62 #mg dose [001] 62 TMC# [001] 62 R ribavirin USP 62 Taxotere ® 62 corticosteroid dose 62 cytarabine daunorubicin 62 dasatinib Sprycel ® 62 hours postdose 62 mesalamine granules 62 3mg 62 dose titration 62 uM 62 mg/# mg [002] 62 darbepoetin alfa 62 mg kg intravenously 62 APTIVUS 62 EURIDIS 62 zolmitriptan 62 ug mL 62 prednisone prednisolone plus 62 cisplatin gemcitabine 62 deferoxamine 62 febrile neutropenia 62 Pegasys peginterferon alfa 2a 62 glatiramer acetate 62 #mg ritonavir 62 ertapenem 62 bortezomib 62 mg Proellex 62 tolterodine ER 62 telaprevir dosing 62 maximally tolerated dose 62 refractory NSCLC 62 #mg dose [002] 62 dalteparin 62 degarelix 62 baseline HbA1c 62 6mg 62 Elitek 62 cyclophosphamide methotrexate 62 postmenopausal osteoporotic women 62 Peginterferon Alfa 2a 62 relapsed refractory multiple myeloma 62 Omacetaxine mepesuccinate 62 blinded randomized placebo controlled 62 glulisine 62 mapatumumab 62 pomalidomide 62 oral alendronate 62 apremilast 62 ABC/3TC 62 5 FU leucovorin 62 Traficet EN 62 lixisenatide 62 HCV SPRINT 62 neurologic progression 62 #.#/#.# mmHg [001] 62 standard chemotherapy regimen 62 ARIKACE 62 COMBIVIR 62 RECIST criteria 62 sUA 62 CANCIDAS 62 forodesine 62 CrCl 62 TAXOTERE R 62 pegylated interferon peg IFN 62 MIRCERA 62 AUC0 62 rotigotine 62 endoscopic remission 62 decitabine 62 inhaled fluticasone 62 valopicitabine 62 -#.# log# 62 intradermal injections 62 relapsed myeloma 62 mitoxantrone plus 62 elagolix 62 aspartate aminotransferase AST 62 tocilizumab 62 Lupuzor ™ 62 ONGLYZA 62 Lantus ® 62 pegylated interferon alfa 62 alanine aminotransferase 62 GSK# [001] 62 tiotropium 62 leucovorin 62 SVR# 62 VIRAMUNE XR 62 ARCOXIA 62 ibandronate 62 remission induction 62 BRIM2 62 tolerated dose MTD 62 HbA1c levels 62 PEG Interferon alfa 61 leuprorelin 61 enfuvirtide 61 maximal tolerated 61 treatment naive genotype 61 tenofovir disoproxil fumarate 61 dose escalation phase 61 undetectable HBV DNA 61 adefovir treated 61 5 Fluorouracil 61 nelfinavir 61 2mg 61 highly emetogenic 61 mEq L 61 MADRS score 61 non splenectomized 61 insulin glulisine 61 -#.# log# copies mL 61 tipranavir 61 receiving VICTRELIS 61 cGy 61 venlafaxine ER 61 pyrazinamide 61 placebo p 61 1mg 2mg 61 FOLFIRI alone 61 carboplatin AUC 61 plus gemcitabine 61 g dL 61 plus OBT 61 triamcinolone 61 Pemetrexed 61 moderate renal impairment 61 insulin degludec 61 log# reduction 61 Primary endpoints 61 randomized #:#:# 61 cells uL 61 atazanavir 61 spontaneous bowel movements 61 insulin glargine 61 peginterferon alpha 2a 61 dosing interval 61 Bezielle 61 chemoradiation therapy 61 pg ml 61 inactive placebo 61 beta2 agonist 61 anthracycline taxane 61 HBeAg negative patients 61 statin monotherapy 61 lanthanum carbonate 61 RGT arm 61 dose limiting toxicities 61 CDAI 61 #/#.# mcg 61 APRISO 61 FFNS 61 zoledronic acid 61 tumor progression TTP 61 Viread Emtriva 61 Welchol 61 mycophenolate mofetil 61 milligram doses 61 docetaxel prednisone 61 RLAI 61 docetaxel Taxotere ® 61 ONGLYZA saxagliptin 61 biologic DMARD 61 gemcitabine cisplatin 61 cilostazol 61 limiting toxicity 61 vinorelbine 61 epoetin beta 61 dasatinib 61 receiving INTRON 61 paliperidone palmitate 61 FEMALES SHOULD BE ADVISED 61 methotrexate monotherapy 61 Phase 2a trial 61 Copegus ribavirin 61 CRp 61 octreotide acetate 61 Sandostatin ® 61 FIRMAGON 61 achieved sustained virologic 61 p = #.# [004] 61 lispro alone 61 -#.# mg dL [002] 61 AEGR 61 mg p = 61 metastatic CRC 61 alanine aminotransferase ALT 61 Chemophase 61 unfractionated heparin UFH 61 CR nPR 61 TO AVOID PREGNANCY WHILE 61 MCyR 61 idraparinux 61 KAPIDEX 61 naïve HCV 61 % Confidence Interval 61 noninferiority 61 nadroparin 61 bronchodilation 61 NATRECOR ® 61 candesartan cilexetil 61 mIU mL 61 pooled comparator 61 zoledronate 61 infusional 5-FU/LV 61 nadolol 61 Median survival 61 Pharmacokinetic parameters 61 KOMBIGLYZE XR 61 daily subcutaneous injections 61 mRCC 61 lenalidomide 61 Index CDAI score 61 ritonavir boosted lopinavir 61 metastatic GIST 61 milligrams mg 61 sitagliptin 61 oblimersen 61 Apidra ® 61 antiretroviral naive 61 detemir 61 visilizumab 61 dapagliflozin plus 61 cyclophosphamide 61 teriflunomide 61 medroxyprogesterone acetate 61 phase Ib 61 Capecitabine 61 primary efficacy endpoint 61 adjunctive ABILIFY 61 valsartan 61 PASI scores 61 ZOLINZA 61 ancrod 61 Tipranavir 61 mg kg BID 61 ISENTRESS 61 fluticasone propionate 61 Pharmacokinetics PK 61 mg/# h 61 dexamethasone 61 LIALDA 61 ongoing Phase 1b 61 glargine 61 humanized interleukin 6 61 Ceplene/IL-2 61 budesonide 61 fluticasone 61 prucalopride 60 SCIg 60 mmol kg 60 neoadjuvant 60 subcutaneous injection 60 HIV RNA 60 darunavir 60 Pegasys R 60 Randomized Phase 60 bolus dose 60 virus HCV protease inhibitor 60 annualized relapse 60 IIIa inhibitors 60 intravesical 60 REMICADE monotherapy 60 mL/min/#.# m 2 60 x ULN 60 relapsed CLL 60 splenectomized 60 PEGylated anti 60 ARB telmisartan 60 nitazoxanide 60 placebo controlled Phase 60 noninferior 60 induction regimen 60 gemcitabine chemotherapy 60 lenalidomide Revlimid R 60 REYATAZ R 60 Free Survival PFS 60 weekly intravenous infusions 60 binary restenosis 60 insulin lispro 60 dose colchicine 60 CorVue ™ 60 kilogram mg kg 60 SYMBICORT 60 ceftriaxone 60 detectable HCV RNA 60 #mg [003] 60 bortezomib refractory 60 Indacaterol 60 coadministration 60 oral methylnaltrexone 60 oral ribavirin 60 SPRYCEL 60 pharmacokinetic parameters 60 nucleoside analog 60 raltegravir 60 formoterol fumarate 60 epirubicin 60 COZAAR 60 HCV RNA 60 albinterferon alfa 2b 60 free survival PFS 60 statistically significant p = 60 MBq 60 cisplatin vinorelbine 60 FluCAM 60 6R BH4 60 low dose dexamethasone 60 titrated glipizide 60 mg/# mg twice 60 composite endpoint 60 quetiapine XR 60 Crohn Disease Activity 60 virologic breakthrough 60 oral antidiabetic medication 60 pioglitazone 60 thalidomide dexamethasone 60 postoperative chemotherapy 60 heavily pretreated patients 60 sitaxsentan 60 LAB GHRH 60 DURATION 60 ALVESCO 60 octreotide 60 tolvaptan 60 plus glycoprotein IIb 60 5FU 60 BEACOPP 60 discontinuations due 60 AGILECT R 60 mg mL 60 complete cytogenetic 60 Copegus 60 GEMZAR 60 atorvastatin #mg 60 neostigmine 60 epoetin alpha 60 Hycamtin ® 60 limiting toxicity DLT 60 nodular partial response 60 Insulin PH# 60 Index CDAI 60 baminercept 60 prior chemotherapy regimens 60 intravenous picoplatin 60 ropivacaine 60 5 fluorouracil 60 docetaxel Taxotere R 60 kg -1 60 MAS XR 60 postintervention 60 CLARITY study 60 Gabapentin GR 60 null responder HCV 60 gemcitabine carboplatin 60 agonist LABA 60 microgram doses 60 mg hydrochlorothiazide 60 9mg 60 AZT zidovudine Retrovir 60 Flu Cy 60 dosing regimens 60 steroid dexamethasone 60 PRADAXA #mg 60 pyrimidine nucleoside analog 60 treatment naïve genotype 60 lamivudine 60 Secondary endpoints 60 oxycodone IR 60 NOXAFIL Oral Suspension 60 sustained virologic response 60 evaluating tivozanib 60 statistically significant p 60 atazanavir sulfate 60 sorafenib tablets 60 achieved CCyR 60 dose dose escalation 60 Darusentan 60 ceftazidime 60 GAMMAGARD 60 prospectively defined 60 Perforomist Inhalation Solution 60 low dose Iluvien 60 HCTZ 60 plus GP IIb 60 mesalamine 60 randomized 60 TYKERB 60 mcg linaclotide 60 plus COPEGUS 60 bosentan 60 severe renal impairment 60 Aflibercept 60 subcutaneous infusion 60 fallopian tube cancers 60 cyclophosphamide doxorubicin vincristine 60 paclitaxel carboplatin 60 TORISEL 60 urinary N telopeptide 60 dose escalation trial 60 zalutumumab 60 CIMZIA TM certolizumab pegol 60 mg FV 60 Lamictal XR 60 goserelin 60 lamivudine refractory patients 60 Contrave# 60 Rating Scale MADRS 60 ZALBIN dosed 59 divalproex sodium 59 ELOXATIN 59 VAPRISOL 59 placebo PBO 59 metformin sulfonylurea 59 melphalan 59 gastric pH 59 LVEF 59 hA# 59 pmol L 59 HBV DNA 59 BARACLUDE ® 59 Amrubicin 59 maximal dose 59 RAPTIVA 59 Psoriasis Area 59 transaminase elevations 59 HGS ETR1 59 FUSILEV enhances 59 PREZISTA rtv 59 EMEND 59 paclitaxel Taxol R 59 TNF antagonists 59 glufosfamide 59 intravenous dose 59 PRADAXA 59 oral ridaforolimus 59 rt PA 59 urate lowering 59 celgosivir 59 amphotericin B 59 oral vancomycin 59 ABRAXANE therapy 59 SEROQUEL XR 59 doxorubicin docetaxel 59 sorafenib Nexavar ® 59 metastatic hormone refractory 59 Coadministration 59 eplerenone 59 1mg 59 CIMZIA 59 serum HBV DNA 59 beclomethasone dipropionate 59 NRTI 59 alvimopan 59 viral kinetics 59 systemic corticosteroid 59 Platinol ® 59 odanacatib 59 leukopenia 59 Lantus R 59 3TC lamivudine Epivir 59 aspirin heparin 59 mometasone furoate 59 pharmacodynamics PD 59 safety tolerability pharmacokinetics 59 emtricitabine tenofovir 59 alfa 2b 59 non inferiority 59 ribavirin USP 59 stage IIIb IV 59 NEXIUM 59 trastuzumab Herceptin R 59 serum HCV RNA 59 response CCyR 59 MabCampath 59 receiving golimumab 59 PEG SN# 59 exenatide 59 PEG Intron ® 59 romiplostim 59 Monotherapy 59 adalimumab Humira 59 EDEMA4 trial 59 Hb A1C 59 ng mL 59 SPRYCEL ® 59 cyclophosphamide vincristine 59 liposome injection 59 gemcitabine Gemzar ® 59 nilotinib 59 Response Evaluation Criteria 59 cytogenetic response 59 abatacept 59 triptorelin 59 double blinded placebo 59 avosentan 59 Exenatide 59 rHuPH# 59 JANUVIA 59 intra articular injection 59 Darunavir 59 TMC# C# 59 MGd 59 pharmacokinetics PK 59 enteric coated naproxen 59 eptifibatide 59 ziprasidone 59 lumbar spine bone 59 placebo capsules 59 intravenously administered 59 RECIST Response Evaluation Criteria 59 severe exacerbations 59 citalopram hydrobromide 59 ixabepilone 59 fasting plasma glucose FPG 59 ketorolac 59 Adalimumab 59 â ‰ ¥ 59 aPTT 59 dosing regimen 59 aplindore 59 Forodesine HCl 59 PRECiSE 59 hour bronchodilation 59 #ug [002] 59 incontinence episodes 59 etoposide 59 boosted protease inhibitor 59 colesevelam HCl 59 oral diclofenac 59 relapsed multiple myeloma 59 AZILECT R 59 cis retinoic acid 59 #mg dosing group 59 dose cytarabine 59 aspartate aminotransferase 59 morphometric vertebral fractures 59 imipenem 59 STELARA 59 glycoprotein IIb IIIa inhibitor 59 interferon ribavirin 59 fludarabine 59 pretreatment baseline 59 ara C 59 complete cytogenetic response 59 MAGE A3 ASCI 59 hypophosphatemia 59 glimepiride 59 tacrolimus 59 intramuscular injections 59 Pegylated Liposomal Doxorubicin 59 CoFactor 59 Sandostatin R 59 Pred Forte 59 mg/# mg [001] 59 % CI #.#-#.# [007] 59 Nasacort AQ 59 splenectomized patients 59 cEVR 59 HBV DNA levels 59 IXEMPRA 59 nevirapine NVP 59 transdermal estradiol 59 XELOX 59 Mg Usa 59 HuMax EGFr 59 isoproterenol 59 docetaxel Taxotere 59 mg BID dose 59 PSA nadir 59 zidovudine lamivudine 59 ACR# responses 59 virologic response 59 valacyclovir 59 Montgomery Asberg Depression 59 unresectable HCC 59 stavudine d4T 59 Bortezomib 59 Raptiva r 59 Linagliptin 59 protease inhibitor PI 59 mGluR5 negative 59 fondaparinux 59 Ondansetron Injection USP 59 irinotecan containing 59 Irinotecan 59 YONDELIS 59 mucosal healing 59 tinzaparin 59 undetectable viral load 59 virological response 59 basal insulin 59 chemoradiotherapy 59 thrombocytopenia 59 REVLIMID lenalidomide 59 P = .# 59 dosing schedules 59 tanespimycin 59 bicalutamide 59 #.#/#.# mm Hg [003] 59 Laquinimod 59 ACTEMRA 59 PREZISTA r arm 59 plus MTX 59 pharmacologically active isomer 59 irinotecan doxorubicin oxaliplatin paclitaxel 59 mg kg REMICADE 59 Pivotal Phase III 59 thymalfasin 59 rifapentine 59 SELZENTRY 59 hydroxymethyl coenzyme 59 trastuzumab 59 intravenous infusion 59 + PH# 58 lacosamide 58 mitoxantrone chemotherapy 58 events AEs 58 Known hypersensitivity